Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT02713867
Brief Title: A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384)

First Submitted : March 11, 2016
First Submitted that Met QC Criteria : March 15, 2016
First Posted : March 21, 2016 (Estimate)

Results First Submitted : March 10, 2020
Results First Submitted that Met QC Criteria : June 2, 2020
Results First Posted : June 22, 2020

Last Update Submitted that Met QC Criteria : June 2, 2020
Last Update Posted : June 22, 2020